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Abstract
Osteocalcin (OCN), a marker of osteoblast activity, has been implicated in the regulation of energy 
metabolism by the skeleton and thus may affect body fat measures. We examined the relationships 
of OCN to body fat measures and whether they vary according to markers of energy and vitamin D 
metabolism. Data was obtained from 58 obese adolescents aged 13–17.9 years (38 females, 8 
black or African-American). We calculated total fat mass (FM) [dual X-ray absorptiometry 
(DXA)] and visceral adipose tissue (VAT) [computerized axial tomography (CT)]. Blood tests 
included leptin, OCN, 25-hydroxyvitamin D [25(OH)D], parathyroid hormone (PTH), thyroid 
function tests, and triglycerides. Markers of glucose metabolism were obtained from fasting and 
OGTT samples. Adolescents with 25(OH)D<20 ng/mL were considered deficient (n=17/58); none 
had high PTH (PTH≥65 pg/mL). OCN was associated with lower VAT (−84.27±33.89 mm2) and 
BMI (−0.10±0.05 kg/m2), not FM (p=0.597) in a core model including age, sex, race, geographic 
latitude, summer, height z-score, and tanner stage. Adding 25(OH)D deficiency and PTH 
attenuated the inverse association of OCN to VAT. We found a significant interaction of OCN and 
25(OH)D deficiency on FM (0.37±0.18 kg, p=0.041) and BMI (0.28±0.10 kg/m2, p=0.007) in this 
adjusted model, which was further explained by leptin. Adding A1C to the core model modified 
the relationship of OCN to VAT (−93.08±35.05 mm2, p=0.011), which was further explained by 
HOMA-IR. In summary, these findings provide evidence for a relationship between OCN and 
body fat measures that is dependent on energy metabolism and vitamin D status among obese 
adolescents.
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INTRODUCTION
There is increasing evidence of a cross-talk between adipose tissue and skeleton (1, 2). 
Osteocalcin (OCN), a marker of osteoblast activity, increases β-cell proliferation, insulin 
secretion, insulin sensitivity (fat, liver, and muscle), and energy expenditure (3). Leptin, a 
marker of adipocyte activity, reduces insulin secretion via several mechanisms and 
modulates Osteocalcin bioactivity (4).
As reviewed by Rauchenzauner (5) and Szulc (6), OCN concentrations may vary with age, 
gender, height, growth velocity, puberty, and time at blood draw. In vitro and in-vivo studies 
have also shown that insulin-like growth factor-I (IGF-I), calcium-dependent hormones such 
as parathyroid hormone (PTH), and metabolites of vitamin D may also affect OCN 
concentrations (7, 8). Higher OCN levels have been observed with exercise during puberty 
in (9) and in some (10) but not all adult studies (11). Lower OCN levels have been described 
among obese children and adolescents who were deficient in vitamin D (12, 13). In addition, 
there is some evidence from in vivo studies that vitamin D may be involved in energy 
metabolism (14). There is initial evidence that testosterone may affect OCN in children and 
adolescents, which is especially relevant during the period of rapid skeletal growth (15), and 
that inflammatory makers are associated with OCN in middle school aged children (16). 
There is also increasing evidence from in vivo studies that OCN may affect insulin 
sensitivity in both adults and children (16–20). Finally, OCN concentration has been 
associated with markers of the metabolic syndrome (21–22) and correlated with body mass 
index (BMI) (and total body fat measured by dual X-ray absorptiometry (DXA) in elderly 
individuals (21, 22) and more recently with markers of energy metabolism and BMI in a real 
life pediatric obesity clinic (20).
Given the significance of bone mass accretion during adolescence and the prevalence of 
obesity and 25(OH)D deficiency, the objective of this cross-sectional study was to assess the 
relationships of OCN with body fat measures and to determine whether these relationships 
varied according to markers of energy metabolism and vitamin D status. We hypothesize that 
the association of OCN and body fat measures may be explained at least in part by markers 
of energy and vitamin D metabolism among obese adolescents.
METHODS AND PROCEDURES
Study subjects and design
We used cross-sectional baseline data from adolescents enrolled in a Glaser Pediatric 
Research Network (GPRN) study of meformin, which is described elsewhere (13, 23, 24). In 
brief, the sample consisted of 58 obese adolescents aged 13.0 to 17.9 y. with a BMI ≥ 95th 
percentile and a weight <136 kg (limit for the DXA-scan). Cross-sectional data included: 1) 
Demographic data (age, gender, race, ethnicity, medication, smoking, illicit drug use, 
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alcohol consumption, month of the year); 2) findings on physical examination (Tanner stage, 
anthropometric measurements); and, 3) laboratory assessments (blood tests, computerized 
axial tomography (CT), and whole-body DXA. None of the adolescents included in this 
study sample had diabetes or other known underlying disorders associated with obesity, had 
participated in a medical or surgical weight loss program, or used medications or substances 
that might affect growth and development, dietary intake, or physical activity.
Vitamin D status and bone metabolism were evaluated using non-fasting plasma samples 
obtained at each of the GCRC at the same time of the day (mid-morning) and stored frozen 
at −70°C until analyzed at the Vitamin D, Skin, and Bone Research Laboratory, Boston MA 
(MFH, TC). Intact OCN was measured using an EIA from Quidel Corporation, CA, USA 
(Intra-assay and inter-assay CVs of 3.4–4.6% and 4.9–5.0%). Other laboratory assays were 
performed at Esoterix Clinical Trials Services, Calabasas Hills, CA; which also provided the 
reference range data used for the analyses. The CT scans were GE, Siemens, or Philips 
equipment, depending on the center (22). The DXA scans were performed using Hologic 
4500 and Delphi-A scanners. Standard phantoms were circulated among four of the five 
GPRN sites for cross-calibration (25). All DXA scans were analyzed at the University of 
California, San Francisco using a standard software program (Hologic Delphi Manual 
software, Beford, MA) and all CT scans were analyzed at Harvard Medical School using a 
standard software program (Photoshop CS2, Adobe Systems, San José, CA).
IRB approvals were obtained from the five GPRN sites (see appendix) and from the Boston 
University School of Medicine. Signed informed consent from a parent or other legal 
guardian of each subject, and age-appropriate assent was obtained prior to study.
Analyses
Data are presented as mean± standard deviation (SD) unless stated otherwise. We used 
correlation coefficients to compare sample characteristics with the independent variable of 
interest for the overall sample and by gender. Statistical significant is defined as p<0.05. The 
outcomes for this cross-sectional data analysis included a variety of body fat measures such 
as total body fat mass (FM, kg), visceral adipose tissue (VAT,mm2), and BMI (kg/m2). Waist 
circumference, measured at the hip (24), was included as a second marker of central body 
fat. The independent variable of interest was OCN (ng/mL).
A number of markers of energy and vitamin D status were selected to evaluate possible 
effect modification on the relationship of OCN to body fat measures. The concentration of 
25(OH)D is currently considered the best indicator of vitamin D status (26, 27). 25(OH)D 
deficiency is presently best defined as concentrations of 25(OH)D <20 ng/mL (26). As none 
of the adolescents had a PTH level above 65 pg/mL (range upper limit) (13), we used PTH 
as a continuous variable in these analyses.
A number of indices were calculated based on fasting and 2 hour oral glucose tolerance test 
(OGTT) samples to estimate insulin resistance and glucose tolerance in relation to body fat 
measures (23, 24). The Homeostasis Model Assessment (HOMA) was calculated as [glucose 
(mM) x insulin (μU/mL)]/22.5 (28) to estimate fasting insulin resistance. Area-under-the-
curve (AUC) for insulin and glucose were calculated from the OGTT data using the 
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trapezoidal rule. None of the adolescents had T2DM, as defined by fasting plasma glucose 
≥126 mg/dL(7 mmol/L) or 2-hr OGTT glucose >200 mg/dL (11.1 mmol/L)(29).
Pearson correlation coefficients were used to assess the associations between continuous 
variables, and point bi-serial coefficients (mathematically equivalent to Pearson correlation 
coefficient) were used to assess the association between continuous and dichotomous 
variables. Spearman correlation coefficients were used to corroborate the Pearson 
correlations and a few minor discrepancies in inference were noted, all cases of borderline p-
value just above or below the conventional p=0.05 cut-off point. No variables were so 
severely skewed in distribution as to require transformation for these analyses. We based our 
judgment that transformation was not required on 1) the close agreement of Pearson and 
Spearman correlations, and 2) the largely symmetric distribution of the dependent variables 
in regression analysis; the median lay within 0.1% of the mean for FM, 2.6% for VAT, 1.6% 
for waist circumference, and 2.5% for BMI.
We used multiple linear regression analysis to model continuous outcomes with Osteocalcin 
after adjusting for potential confounding variables. Covariates included variables suggested 
in the literature and those found to be significant in univariate analysis. We examined 
whether markers of energy glucose metabolism modified the relationship of OCN to VAT. 
We also examined whether PTH and 25(OH)D deficiency modified the relationships of OCN 
to VAT.
We used the multivariate models to test for interactions between relevant variables. We 
created an interaction term to evaluate the effect of increasing levels of OCN among vitamin 
D deficient adolescents on body fat measures. Interaction terms between OCN and gender or 
race were not found to be significant (p for interaction >0.05) and thus were not included in 
the results section. As an example, the association between OCN and body fat measures did 
not vary significantly by gender (p for interaction = 0.736 for FM, p for interaction = 0.341 
for VAT, p for interaction = 0.957 for WC, and p for interaction = 0.802 for BMI). Given that 
the interactions were not significant, further stratification of the data to identify whether the 
associations between OCN and body fat measures varied according to gender were not 
performed.
Among the outcome variables, three CT-scan measures and one waist circumference 
measure were missing. A physical activity measure based on accelerometer was only 
available for 24 of the 58 adolescents.
Based on a two-sided test at 0.05, a sample of 58 subjects provided 80% power for detecting 
a correlation coefficient of 0.35 between two variables, or for detecting an R2 of 0.12, 0.20, 
and 0.26 using multiple linear regression analyses with one, six and eleven variables. 
Analyses were performed using STATA (version 8). Given that the sample size for male 
adolescents (n=20) and for female adolescents (n=38) were much smaller, magnitude, not 
strength of associations between sample characteristics and OCN were presented.
Lenders et al. Page 4
Obesity (Silver Spring). Author manuscript; available in PMC 2016 May 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
RESULTS
The overall sample OCN concentration was 44.7±21.9 ng/mL while OCN concentrations 
were 59.6±22.3 ng/ml for the boys and 36.9±17.3 ng/mL for the girls. The overall sample 
VAT was 7436.5±3632.7 mm2 and FM 39.9±9.8 kg, which corresponded to a VAT of 
12.4±4.3% and FM of 40.0±5.5 %. Waist circumference was 105.7±12.1 cm. BMI was 36±5 
kg/m2 and 29 of the 58 subjects (50%) had a BMI between the 99.0 and 99.9th percentile. A 
total of 17 subjects (29%) had a 25(OH)D level below 20 ng/mL (25(OH)D deficiency). As 
previously reported (13), none of the subjects had an abnormal PTH concentration, as the 
highest value was 48 pg/mL. The HOMA-IR index was 4.5±3.2 and the HbA1C was 
5.4±0.3 %, with one subject at 6.5%, but all had normal OGTTs.
In the overall sample, we found a strong correlation between gender and OCN (r=0.50). 
OCN was directly correlated with Tanner stage and geographic latitude (P<0.05) and 
inversely correlated with age (p<0.05, Table 1). There were no significant correlations 
between OCN and black or African American race, summer, or height z-score (p>0.05). 
Metabolic factors directly associated with OCN included TSH (r=0.28), IGF1 (r=0.31), and 
IGFBP-1 (r=0.48) p<0.05, while 25(OH)D (r=−0.28) and T4 (r=−0.30) were negatively 
associated with OCN (p<0.05), but none of the other metabolic factors examined were 
significantly associated with OCN (p>0.05). Overall, the correlations coefficients between 
sample characteristics and OCN for male and female adolescents were similar except for 
leptin and the markers of carbohydrate and lipid metabolism.
Relationshipof Osteocalcin to body fat measures
In simple regression analysis (Table 3), each increment of 1ng/mL OCN was inversely 
associated with FM (−0.12±0.06 kg, p=0.047) and BMI (−0.11±0.03 kg/m2, p=0.001) but 
not with VAT (−33.31±21.95 mm2, p=0.135). After adjusting for age, gender, black or 
African-American race, geographic latitude, summer season, height z-score, and Tanner 
stage 2–3, OCN was significantly and inversely associated with VAT (−84.27±33.89 mm2, 
p=0.017) and BMI (−0.10±0.05 kg/m2, p=0.037), but not with FM (−0.04±0.08 kg, 
p=0.597). The association of OCN and waist circumference was similar to those of OCN 
and VAT in multivariate analysis.
Effect modification of vitamin D status
The addition of 25(OH)D deficiency and PTH to the core model did not affect the 
relationship of OCN to BMI (−0.11±0.05 kg/m2, p=0.020) but attenuated the inverse 
relationship of OCN to VAT (−74.40±37.39 mm2, p=0.053). However, vitamin D deficient 
adolescents with higher OCN levels were more likely to have higher FM (0.37±0.18 kg, 
p=0.041) and BMI (0.28±0.10 kg/m2, p=0.007) but not VAT (102.95±83.34 mm2, p=0.223) 
compared to those who were not deficient with higher OCN levels.
As some investigators have suggested that leptin modulates OCN activity, we further 
evaluated the effect of leptin on the relationship of OCN and body fat measures as well as 
the interaction term between OCN and 25(OH)D deficiency on body fat measures. The 
addition of leptin to the core model with PTH, 25(OH)D deficiency, and the interaction term 
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between 25(OH)D deficiency and OCN did not attenuate the relationship of OCN to body 
fat measures but explained the relationship of the interaction term to FM and BMI.
Effect modification of markers of glucose metabolism
Markers of insulin resistance such as fasting insulin, HOMA-IR, and the area-under-the-
curve for insulin attenuated the relationships of OCN to VAT and BMI. As an example, the 
relationship of OCN to VAT was modified from −84.27±33.89 mm2 (p=0.017) to 
−62.56±35.75 mm2 (p=0.087; Table 4) by HOMA-IR.
The relationship of OCN to VAT also varied with markers of glucose tolerance such as the 
area-under-the-curve glucose, fasting glucose, and HbA1C. The direction of the relationship 
between OCN and VAT varied with the markers. The area-under-the-curve glucose 
explained the association between OCN and VAT (−56.20±36.38, p=0.130; data nor shown), 
no magnitude change was observed between OCN and VAT (−86.14±33.92, p=0.015; data 
not shown) for fasting glucose, but there was a stronger inverse association between OCN 
and VAT (−93.08±35.04, p=0.011; Table 4) for HbA1C. However, the addition of 
HOMA_IR to the core model with A1C explained the relationship of OCN to VAT 
(−69.98±38.00, p=0.073). In addition, the relationship of OCN to VAT was attenuated by 
markers of lipid metabolism, growth, and the thyroid axis (Table 4).
DISCUSSION
Overall, the study findings indicate that VAT and BMI are inversely associated with OCN. 
To our knowledge, this is the first study to suggest that the relationship of OCN to body fat 
measures in obese adolescents is dependent on markers of energy and vitamin D status.
Data indicating a reciprocal relationship between bone and energy metabolism comes 
primarily from animal studies (2), with limited data in humans. A recently published study 
in elderly individuals demonstrated an association between OCN and several plasma 
markers of energy metabolism and body fat measures (21). This cross sectional study of 380 
obese adults 65 years old and older showed an inverse relationship between OCN and body 
fat measures (including DXA) before and after adjusting for age, gender, physical activity, 
smoking, and education. Similarly, we used a multivariate model to assess the relationship 
between OCN and body fat measures. Covariates included age, gender, black or African-
American race, geographic latitude (North of Atlanta), summer, height z-score, and Tanner 
stage 2–3 vs. 4–5. After adjusting for these covariates, we found a similar inverse 
association between OCN and body fat measures (Table 3).
In our study population, 21% were in an early to mid pubertal stage (Tanner stage II-III), 
when the velocity of linear growth is expected to be at its peak, and 29% of the individuals 
were considered to be Vitamin D deficient. In Reinehr’s study 57% of the children were pre-
pubertal (Tanner stage 1) but data on 25(OH)D deficiency was not available. Previous 
pediatric studies have shown greater levels of OCN during linear growth but lower levels 
among adolescents with 25(OH)D deficiency and among obese pre-pubertal African 
American children (12). Using a sample of obese adolescents of mixed race/ethnicity, we 
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confirmed that individuals at Tanner stage II-III were more likely to have higher OCN levels 
and those with 25(OH)D deficiency were more likely to have lower OCN.
In our study sample, PTH levels were found to be within the normal range but were higher 
among obese adolescents Tanner stage II-III and among those with 25(OH)D deficiency 
(13). There is some evidence that PTH may activate the transcription of the Osteocalcin 
promoter (8) and thus affect OCN in the plasma, however the effect of PTH on the osteoblast 
is still controversial (31). Based on current available data from studies of 25(OH)D 
deficiency and PTH levels, we cannot exclude the possible opposite relationship of PTH and 
25(OH)D deficiency to body fat measures. In our study, the inverse association of 
Osteocalcin to VAT was attenuated by the addition of 25(OH)D deficiency and PTH to the 
model (Table 3).
Menendez (32) found that 25(OH)D may inhibit in vitro leptin secretion by adipose tissue 
but Tarcin et al. (14) found that leptin levels were positively correlated with 25(OH)D in 
vivo. Although the relationship between leptin and 25(OH)D remains unclear, it has been 
suggested that leptin may be involved in the regulation of OCN activity via several 
mechanisms (3). A previous pediatric obesity study showed that leptin was inversely 
correlated with OCN in a sample of younger and mostly pre-pubertal obese children (20). 
We found an inverse correlation of leptin to OCN but these correlation coefficients were 
smaller and non-signifcant. In our study, the interaction between OCN and 25(OH)D 
deficiency on FM and BMI was significant, but this effect was further explained by leptin 
levels. After adjusting for all covariates, OCN was strongly and inversely associated with 
VAT, WC, and BMI, but not with FM.
There is evidence from animal models (3) and adult studies (16–22, 33–34) affect glucose 
metabolism, and thus body fat measures. In our study sample, we found that A1C affected 
the relationship of OCN with body fat measures (VAT, WC, and BMI), which was further 
explained by HOMA-IRI. In our study, levels of HOMA_IR index (5.45±3.19, Table 2) were 
higher and showed more variation than those of Reinehr (3.5±0.3). As opposed to our study, 
Reinehr (20) found a significant inverse association between OCN and HOMA-IR in 
univariate analysis, but data on A1C and relationships of OCN to other body fat measures 
were not available.
OCN has not only been shown to raise insulin secretion and improve insulin sensitivity (3, 
34) but there is also increasing evidence that OCN may be related to improved glycemic 
control in adults with T2DM (32, 35).
We are further intrigued by the effect of thyroid function tests on the relationship of OCN 
and body fat measures. We observed an attenuation of the relationship between OCN and 
VAT but not between OCN and other body fat measures when TSH and T4 were included in 
the core model (Table 4). Although, there is limited evidence of an association between TSH 
and OCN, there is evidence of an association between TSH and body fat measures. In fact, 
central fat accumulation has previously been associated with elevated TSH in adults (37, 
38). To the best of our knowledge, this is the first study to suggest that measures of thyroid 
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function may modify the relationship between OCN and body fat measures in obese 
adolescents.
The limitations of this study include a cross-sectional design, which does not provide 
information on causality. As opposed to Boucher-berry, we did not have information on 
undercarboxylated and caboxylated OCN (16), but rather on OCN which is highly correlated 
with under-carboxylated and possibly a better marker for insulin sensitivity. Like Reinehr 
(20) and Boucher-Berry (16), we did not have data on sex hormones but we had data on 
Tanner stage. Therefore, we were able to adjust for the pubertal stage at the peak of skeletal 
growth when testosterone changes are most relevant. Our results are consistent with prior 
causal relationships identified in previous animal and human studies. Although our findings 
cannot be generalized to all populations, they may indicate directions for future 
investigation. Despite a limited sample size, we were able to provide initial evidence for a 
relationship between OCN and body fat measures, which may vary according to metabolic 
factors.
In conclusion, our study findings provide initial insight into the relationships of and body fat 
measures among obese adolescents during puberty and may serve as an important first step 
for future research into metabolic factors influencing adolescent obesity.
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